PLAINVIEW, N.Y., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Vaso Corporation (“Vaso”) (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and healthcare IT services, professional sales services and proprietary medical products, today announced operating results for the three months ended September 30, 2025. “For the third quarter of 2025, the Company’s total revenue was $22.7 million, an increase of $1.9 million, or 9.1%, from prior year’s third quarter revenue of $20.8 million. ...

Core Viewpoint - Vaso Corporation reported a slight decline in revenue for Q2 2025, primarily due to lower performance in the professional sales service segment, while maintaining a strong balance sheet with significant deferred revenue growth [2][3][6]. Financial Performance - Revenue for Q2 2025 was $20.0 million, a decrease of 1.3% from $20.2 million in Q2 2024, mainly driven by a 4.0% decline in the professional sales service segment [3][4]. - Gross profit for the quarter was $11.8 million, down by $354 thousand or 2.9% year-over-year [4]. - The company reported a net loss of $197 thousand for Q2 2025, compared to a net income of $1.2 million in the same quarter of 2024 [6][7]. Segment Performance - Revenue in the professional sales service segment decreased by $366 thousand, while the IT segment saw a slight increase of $93 thousand, and the equipment segment rose by $4 thousand [3]. - Selling, general and administrative (SG&A) expenses increased by $1.2 million or 11% to $12.1 million, primarily due to higher personnel costs [5]. Cash Flow and Balance Sheet - Operating cash flow for the three months ended June 30, 2025, was $6.8 million, contributing to a strong cash position of $32.6 million at the end of the reporting period [2][8]. - Total current assets were $49.972 million, and total stockholders' equity was $26.501 million as of June 30, 2025 [15]. Outlook - The company remains cautiously optimistic about the full year 2025, historically achieving better profitability in the later quarters [2].